Surgery Training News Today

An organization of doctors protested at a regents meeting due to the Anschutz Medical Campus' purported use of live pigs for surgery training.

A student in the U.K. has developed a penis simulator that doctors can use to train for surgeries that involve penile implants. Key details: With realistic anatomical structures, the urogenital simulator provides a "lifelike training environment" and serves as an ethical alternative to cadavers for inflatable penile prosthesis (IPP) surgery training, according to a news release. It was developed by Zixi Wang, an undergraduate physics honors student from King's College London who w...

Edwards Lifesciences' Promotional Bus Tour Gives Surgeons in Europe Advanced Heart-Valve Surgery Training

Since 2012, in order to reduce the global treatment gap, the FIGO Fistula Surgery Training Initiative has been building the capacities of local trainee fistula surgeons – ‘FIGO Fellows’ – and multidisciplinary care teams to provide treatment for women suffering from obstetric fistula in some of the world’s most underserved communities.

/PRNewswire/ -- The "Global New Form Factors Market 2022 - Growing 5G and AI to Boost Demand Worldwide" report has been added to ResearchAndMarkets.coms...

Some Baltimore City school students said their future is brighter because of a special partnership with the University of Maryland Medical Center.

Obstetric fistula is a neglected public health and human rights issue. A devastating childbirth injury that leaves women permanently incontinent unless they receive treatment by a trained, competent fistula surgeon.   

Exploring controversies in treatment at the Israel Forum  The fifth day of the FIGO 2021 World Congress started with a session on controversies in treatment, taking place live at the Israel Forum and streamed directly onto our virtual platform. During this session, a fascinating debate took place on the use of valaciclovir to prevent vertical transmission of cytomegalovirus. Dr Yacov Amir spoke first, taking the stance that valaciclovir is an effective form of treatment, followed ...

 E-Mail Interim data from a phase 3 trial of a COVID-19 vaccine developed in China (CoronaVac) suggests that two doses offer 83.5% protection against symptomatic COVID-19. The preliminary findings, published in The Lancet and presented at this years European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), indicate that CoronaVac induces a robust antibody response. No severe adverse events or deaths were reported among the more than 10,000 trial participants in Turkey, with m...